EU indices mixed | TA focus on Novartis

,

European stocks report | BP | Santander | Novartis...

Stocks (2)

INDICES
Yesterday, European stocks were deeply in the red. The Stoxx Europe 600 Index dropped 1.81%, Germany's DAX 30 plunged 3.71%, France's CAC 40 lost 1.90% and the U.K.'s FTSE 100 was down 1.16%.

EUROPE ADVANCE/DECLINE
92% of STOXX 600 constituents traded lower or unchanged yesterday.
26% of the shares trade above their 20D MA vs 45% Friday (below the 20D moving average).
52% of the shares trade above their 200D MA vs 60% Friday (above the 20D moving average).

The Euro Stoxx 50 Volatility index added 3.6pts to 31.76, a new 52w high.

SECTORS vs STOXX 600
3mths relative high: Autos, Media, Utilities
3mths relative low: Technology, Energy

Europe Best 3 sectors
travel & leisure, automobiles & parts, banks

Europe worst 3 sectors
technology, basic resources, chemicals


INTEREST RATE
The 10yr Bund yield fell 1bp to -0.57% (below its 20D MA). The 2yr-10yr yield spread rose 1bp to -18bps (below its 20D MA).


ECONOMIC DATA
FR 08:45: Sep PPI MoM, exp.: 0.1%
EC 10:00: Sep Loans to Companies YoY, exp.: 7.1%
EC 10:00: Sep M3 Money Supply YoY, exp.: 9.5%
EC 10:00: Sep Loans to Households YoY, exp.: 3%
FR 12:00: Sep Unemployment Benefit Claims, exp.: -171K
FR 12:00: Sep Jobseekers Total, exp.: 3621.5K
UK 12:00: Oct CBI Distributive Trades, exp.: 11


MORNING TRADING
In Asian trading hours, EUR/USD rebounded to 1.1820 and GBP/USD bounced to 1.3035. USD/JPY slipped to 104.70.

Spot gold climbed to $1,909 an ounce.


#UK - IRELAND#
BP, an oil giant, reported that 3Q underlying replacement cost profit slumped to 86 million dollars from 2.25 billion dollars in the prior-year period, and compared with an underlying replacement cost loss of 6.68 billion dollars in the prior quarter. The company said: "Compared to the previous quarter, the result benefitted from the absence of significant exploration write-offs and recovering oil and gas prices and demand. This was partly offset by a significantly lower oil trading result. (...) A dividend of 5.25 cents per share was announced for the quarter."


#FRANCE#
Orange, a telecommunications group, was upgraded to "equalweight" from "underweight" at Morgan Stanley.


#SPAIN#
Santander, a Spanish bank, announced that 3Q underlying profit dropped 18% on year to 1.75 billion euros on net interest income of 7.77 billion, up 1%. The bank stated: "The bank has improved its outlook on cost of credit in 2020 to c.1.3% from its previous guidance of 1.4-1.5%, due to the positive trends in customer behaviour and better macro forecasts. This better outlook, paired with strong cost control, give the bank reason to expect an underlying profit of around E5 billion for the year."


#SWITZERLAND#
Novartis, a Swiss multinational pharmaceutical group, posted 3Q core net income rose 8% on year to 3.47 billion dollars and core operating income increased 9% to 4.07 billion dollars on net sales of 12.26 billion dollars, up 1% (flat at constant currency). The company has raised its full-year core operating income growth forecast to "low double digit to mid teens" from "low double digit" previously and expects net sales to grow mid single digit.

From a technical point of view, the stock is rebounding from the lower end of the short term trading range at 75CHF. As long as this key level is support, readers may consider the potential for opening long positions with the overlap area at 79.3CHF and the previous top of September at 84CHF as targets. Alternatively, a break below 75CHF would call for a new down leg towards 69.9CHF.


Source: TradingView, GAIN Capital

#FINLAND#
UPM-Kymmene, a Finnish forest industry company, is expected to report 3Q results.

More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.